Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.

Shen J, Wei J, Wang H, Yue G, Yu L, Yang Y, Xie L, Zou Z, Qian X, Ding Y, Guan W, Liu B.

J Transl Med. 2013 Mar 22;11:73. doi: 10.1186/1479-5876-11-73.

2.

Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.

Yue G, Wei J, Qian X, Yu L, Zou Z, Guan W, Wang H, Shen J, Liu B.

PLoS One. 2013 Jun 7;8(6):e65164. doi: 10.1371/journal.pone.0065164. Print 2013.

3.

Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer.

Wang L, Xie L, Wang J, Shen J, Liu B.

BMC Gastroenterol. 2013 Dec 23;13:173. doi: 10.1186/1471-230X-13-173.

4.

SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen.

Shen J, Wei J, Wang H, Yang Y, Yue G, Wang L, Yu L, Xie L, Sun X, Bian X, Zou Z, Qian X, Guan W, Liu B.

PLoS One. 2013 Oct 4;8(10):e75564. doi: 10.1371/journal.pone.0075564. eCollection 2013.

5.

[Correlation between the methylation of SULF2 and WRN promoter and chemosensitivity to irinotecan in gastric cancer].

Wang L, Shen J, Meng LJ, Fan WF, Wang J, Liu BR.

Zhonghua Zhong Liu Za Zhi. 2013 Jun;35(6):418-22. Chinese.

PMID:
24119900
6.

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.

Buhl IK, Gerster S, Delorenzi M, Jensen T, Jensen PB, Bosman F, Tejpar S, Roth A, Brunner N, Hansen A, Knudsen S.

PLoS One. 2016 May 12;11(5):e0155123. doi: 10.1371/journal.pone.0155123. eCollection 2016.

7.

Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.

Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, Arango D.

Clin Cancer Res. 2010 Apr 15;16(8):2375-82. doi: 10.1158/1078-0432.CCR-09-3275. Epub 2010 Apr 6.

8.

SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.

Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, Liu Y, Dacic S, Siegfried JM, Dahlberg SE, Schiller JH, Belinsky SA.

Oncogene. 2012 Sep 13;31(37):4107-16. doi: 10.1038/onc.2011.577. Epub 2011 Dec 12.

9.

ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.

Subhash VV, Tan SH, Yeo MS, Yan FL, Peethala PC, Liem N, Krishnan V, Yong WP.

Mol Cancer Ther. 2016 Dec;15(12):3087-3096. Epub 2016 Sep 16.

PMID:
27638859
10.

Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.

Emmink BL, Van Houdt WJ, Vries RG, Hoogwater FJ, Govaert KM, Verheem A, Nijkamp MW, Steller EJ, Jimenez CR, Clevers H, Borel Rinkes IH, Kranenburg O.

Gastroenterology. 2011 Jul;141(1):269-78. doi: 10.1053/j.gastro.2011.03.052. Epub 2011 Apr 1.

PMID:
21459094
11.

Up-regulated expression of sulfatases (SULF1 and SULF2) as prognostic and metastasis predictive markers in human gastric cancer.

Hur K, Han TS, Jung EJ, Yu J, Lee HJ, Kim WH, Goel A, Yang HK.

J Pathol. 2012 Sep;228(1):88-98. doi: 10.1002/path.4055. Epub 2012 Jul 18.

PMID:
22653794
12.

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.

Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K.

Br J Cancer. 2008 Feb 26;98(4):832-9. doi: 10.1038/sj.bjc.6604211. Epub 2008 Jan 29.

13.

Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.

Yamada Y, Boku N, Nishina T, Yamaguchi K, Denda T, Tsuji A, Hamamoto Y, Konishi K, Tsuji Y, Amagai K, Ohkawa S, Fujita Y, Nishisaki H, Kawai H, Takashima A, Mizusawa J, Nakamura K, Ohtsu A.

Ann Oncol. 2013 Oct;24(10):2560-5. doi: 10.1093/annonc/mdt238. Epub 2013 Jul 24.

PMID:
23884439
14.

Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer.

Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X, Yu L, Zou Z, Xie L, Costa C, Bivona T, Rosell R, Liu B.

J Transl Med. 2014 Dec 14;12:355. doi: 10.1186/s12967-014-0355-2.

15.

FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.

Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q.

Clin Cancer Res. 2013 May 1;19(9):2572-83. doi: 10.1158/1078-0432.CCR-12-3898. Epub 2013 Mar 14.

16.

A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response.

Busuttil RA, George J, Tothill RW, Ioculano K, Kowalczyk A, Mitchell C, Lade S, Tan P, Haviv I, Boussioutas A.

Clin Cancer Res. 2014 May 15;20(10):2761-72. doi: 10.1158/1078-0432.CCR-13-3049. Epub 2014 Mar 21.

17.

Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.

Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC.

Cancer Biol Ther. 2015;16(5):764-9. doi: 10.1080/15384047.2015.1026479. Epub 2015 Mar 16.

18.

An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.

Yashiro M, Qiu H, Hasegawa T, Zhang X, Matsuzaki T, Hirakawa K.

Br J Cancer. 2011 Nov 8;105(10):1522-32. doi: 10.1038/bjc.2011.397. Epub 2011 Oct 13.

19.

Gene expression signature-based prognostic risk score in gastric cancer.

Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, Noh SH, Park ES, Chu IS, Hong WK, Ajani JA, Lee JS.

Clin Cancer Res. 2011 Apr 1;17(7):1850-7. doi: 10.1158/1078-0432.CCR-10-2180. Epub 2011 Mar 29.

20.

Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.

Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P.

Anticancer Drugs. 2001 Oct;12(9):741-51.

PMID:
11593056

Supplemental Content

Support Center